Developing a PrEP for HIV Prevention

Partnership objective

To help slow the spread of the HIV virus by developing a long-acting injectable antiretroviral (ARV) as a potential pre-exposure prophylaxis (PrEP) agent. 

PrEP is a new and emerging HIV prevention tool in which HIV-negative individuals take an ARV to reduce their risk of acquiring the virus. PrEP is a new and emerging HIV prevention tool in which HIV-negative individuals take an ARV to reduce their risk of acquiring the virus. Copyright Johnson & Johnson

What are the health needs and challenges?

Approximately 2 million people die from AIDS each year worldwide, with a disproportionate loss of life in sub-Saharan Africa. Halting the incidence of new infections will require a range of biomedical HIV prevention strategies, including PrEP, microbicides, barrier contraception, and voluntary medical male circumcision, as well as providing treatment to those living with HIV.

PrEP is a new and emerging HIV prevention tool in which HIV-negative individuals take an ARV to reduce their risk of acquiring the virus. If it is delivered effectively and targeted to those at highest risk, PrEP may play a role in helping to reduce the number of new HIV infections globally. 

Description of partnership activities and how they address needs and challenges

Janssen Pharmaceutical Companies of Johnson & Johnson and its partner Program for Appropriate Technology in Health (PATH) are exploring innovative applications of HIV medicines to improve treatment outcomes in hard-to-reach areas by finding ways to reduce the frequency of dosing.

In September 2013, Janssen R&D Ireland signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential PrEP against HIV infection.

Summary of impact and forward looking information:

Under the terms of the agreement, a Drug Development program of PATH, an international nonprofit organization that transforms global health through innovation, has the right to develop rilpivirine long-acting formulation as a possible new way to prevent HIV infection. PATH has the intent to conduct prophylaxis clinical trials in collaboration with partners including the HIV Prevention Trials Network. Following the completion of the clinical Phase 2 program, PATH and Janssen will evaluate entering into a late stage development agreement covering the use of rilpivirine as PrEP for uninfected individuals at high risk of acquiring HIV.

Partnership information

Company(ies) Johnson & Johnson

Partner(s) PATH

Type of Partner(s) NGOs

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Program Type(s) Availability of Treatment - Technology Transfer - Scientific Collaboration and Knowledge Sharing, Research & Development - Development of Treatments

Targeted Population(s) Men, Mothers, People with low income, Women, Youth

Region(s) Sub-Saharan Africa

Number of Countries 48

Country(ies) Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, The Gambia, Togo, Uganda, Zambia, Zimbabwe

Start Date 2013

More information Press Release

Anticipated completion date Ongoing